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Abstract 
 
Objective: To aim the vitamin D level in patient with pulmonary hypertension and right 
ventricular systolic dysfunction. 
 
Patients and methods: This case-control study was conducted on twenty five patients 
with pulmonary hypertension who were admitted to Merjan Teaching Hospital in Al- 
Hilla, Babylon-Iraq, during the period from June to December 2016. There were 13 males 
and 12 females among the patients; ages of them ranged from 39 to 80 years with a mean 
age of 59.50±11.881 years. The controls were equal in number to the patients and were 
relatives of them; they were healthy with respect to any cardiac or pulmonary morbidity; 
and were matched by age and gender. Blood samples were collected from both groups  
to estimate the level of vitamin D and transthoracic echocardiographic studies were done 
for them to evaluate right ventricular systolic pressure (RVSP) and tricuspid annular plane 
systolic excursion (TAPSE) to assess right ventricular systolic function. 
 
Results: The study results demonstrated that there was a statistically significant dif- 
ference between patients and controls regarding vitamin D level, right ventricular systolic 
pressure (RVSP) and tricuspid annular plane systolic excursion (TAPSE) . 
 
Conclusion: Vitamin D deficiency is more frequent and prevalent among patients with 
Pulmonary hypertension and right ventricular systolic dysfunction compared to con- trol 
group of subjects. Future large scale studies are therefore warranted to validate benefit of 
supplementing vitamin D in patients at risk for pulmonary hypertension who are likely to 
be vitamin D deficient. 
 
Keywords: Vitamin D, pulmonary hypertension, right ventricular systolic pressure , 
tricuspid annular plane systolic excursion, right ventricular systolic function,. 
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ىدل مدلا في )د( ينماتيف ىوتسم لوح ةسراد  ةئافك مدعو يوئرلا مدلا طغض عافترا ىضرم
يضابقنلاا نيملأا ينطبلا صحف ةطساوب ينصخشلما ةبلقلا ىدص 
 
يرومعملا رباج يلع 
 
بطلا ةيلكلباب ةعماج 
 
 
. 
1 -Introduction 
Vitamin D has a significant role in the regulation of musculoskeletal stability and 
home- ostasis of the body [1] . The pathogenesis of many chronic illnesses such as 
diabetes, elevated blood pressure and several types of infections have been linked to 
deficiency of vitamin D [2] . Blood pressure control appears to be having an association 
with vitamin D via numerous paths and is inversely associated with serum renin activity 
[3]. Vitamin D can block the action of renin, and this seems to be resulting from 
elevated intracellular calcium levels [4] 
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Lack of vitamin D triggers the renin-angiotensin-aldosterone pathway and increases 
the susceptibility to hypertension [5] . Vitamin D has an effect on vascular endothelial 
growth factor and endothelin expression and can predispose to endothelial dysfunction [6] 
. 
Deficiency of Vitamin D weakens its protective effects against fibrosis, myocardial 
fiber thickening and anti-apoptosis, leading to cardiac wall thickening and finally dilata- 
tion. It has been also noticed that deficiency of vitamin D causes myocardial hypertrophy 
and extracellular matrix deposition in myocardium. Harmful effects connected to vitamin 
D excess include hyperphosphatemia, hypercalcaemia, elevated matrix metalloproteinase 
and arterial stiffness [7] 
 
Pulmonary hypertension signifies a group of disorders that leads to various pulmonary 
vascular changes like vasoconstriction, endothelial and smooth muscle tissue proliferation 
that ensues to a persistently elevated pulmonary arterial pressure [8] . This results in right 
sided cardiac failure and a significant decrease cardiac output with subsequent mortal- 
ity [9] . As the main pathological mechanisms of elevated pulmonary arterial pressure are 
linked to vasoconstriction, thrombosis and inflammation, it can be suggested that vitamin 
D deficiency may exert an incorrect outcome on the progress of pulmonary hyperten- 
sion [10] (Heidari, B. et al 2015). In addition, activation of renin-angiotensin-aldosterone 
pathway that results from vitamin D lack is connected to an elevated pulmonary arterial 
pressure [2] . 
 
A significant target tissue for vitamin D special effects on genomic and non-genomic 
levels is the cardiac muscle. Cardiac muscle cells express vitamin D receptors, and some 
researches in rodents showed that this vitamin has a protective effect regarding cardiac 
muscle hypertrophy and malfunction [11] . 
 
Vitamin D-mediated cardiovascular illness is a subject of extensive discussions by 
many researchers; for example, Pilz et al [12] had measured the level of vitamin D in 
Caucasian patients as they were referred for coronary angiography and they concluded 
that the deficiency of this vitamin is associated with myocardial dysfunction, cardiac fail- 
ure, and sudden cardiac death. 
 
Some evidences demonstrated that vitamin D possesses three principal cardiac- 
protective mechanisms: Suppressing renin gene expression; presence of vitamin D 
receptors in cardiac myocytes, besides that lack of vitamin D activates secondary 
hyperparathyroidism, which in turn indorses cardiac hypertrophy [13] 
The main objective of this study is to inspect the influence of vitamin D deficiency on 
the prevalence of pulmonary hypertension. 
2 -Patients and methods 
This case-control study was conducted on twenty five patients with pulmonary 
hyperten- sion who were admitted to Merjan Teaching Hospital in Al-Hilla, Babylon-
Iraq, during the period from June to December 2016. There were 13 males and 12 
females among  the patients; ages of them ranged from 39 to 80 years with a mean age 
of 59.50±11.881 years. The controls were equal in number to the patients and were  
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relatives of them; they were healthy in respect for cardiac or pulmonary morbidity; and 
were matched by age and gender. 
 
The diagnosis of pulmonary hypertension was accomplished by transthoracic 
echocardiography by measuring right ventricular systolic pressure (RVSP) and tricuspid 
annular plane systolic excursion (TAPSE) to evaluate right ventricular systolic function . 
Echocardiographic evaluations employed colored Doppler and two-dimensional transtho- 
racic studies with a cardiac ultrasound machine GE-Medical Systems XDclear E9 USA 
2014 equipped with 2.5 MHz multifrequency array transducer. Applying continuous 
wave doppler of the Tricusped valve by the apical four chambers view to measure the 
maximal tricuspid regurgitation velocity to estimste RVSP . Patient with right ventricular 
systolic pressure of more than 40 mmhg ( correspond to mean pulmonary artery pressure 
of 25 mmhg) were diagnosed as pulmonary hypertension. Patient with Tricuspid annular 
plane systolic excursion of 1.5 cm or less were diagnosed with right ventricular systolic 
dysfunction. Exclusion criteria were liver or renal impairments; presence of congenital 
heart disease, ischemic heart disease, moderate to severe valvular heart disease or heart 
failure (ejection fraction less than 55%), presence of chronic pulmonary diseases, thyroid 
or parathyroid diseases, hypertension , diabetes mellitus and those patient with poor 
image quality by by transthoracic echocardiography. Baseline data, including age and 
gender and laboratory data including estimation of vitamin D level were all collected 
from both patients and controls. 
 
Blood samples for the estimation of vitamin D level were collected into an EDTA 
tubes and were analyzed by the use of vitamin D total kit utilizing ELISA technology [14] 
. 
3 -Ethical approval: 
Written and verbal consent agreement were obtained from each subject participated 
in this work .Moreover, this work was approved by a research ethical committee in 
College of medicine –Babylon University /Iraq. 
 
4 -Statistical analysis 
Numeric data (age, vitamin D level, RVSP and TAPSE) were stated as mean ± 
standard deviation (SD), while the other string data (gender) were stated as percentages. 
Patients and controls were compared using independent-samples t-test for the numeric 
data and chi-square test for the string data.  All tests were established by the use of 
SPSS ver-sion 18.0 software (SPSS Inc., Chicago, IL, USA). p<0.05 was encountered 
statistically significant. 
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5 -Results 
Age and gender distributions are stated in tables (1) and (2) which showed no 
significant difference between study groups regarding them (p values=0.991 and 0.571, 
respectively). 
 
FIGURE 1: Agedistribution of patients with pulmonaryhypertension and control group. 
 
 
FIGURE 2: Gender distribution Of patients with pulmonaryhypertension and control group 
 
FIGURE 3: Vitamin Dlevel for patients with pulmonary hypertension and control group. 
 
 
 
 
FIGURE 4: Rightventricular systolic pressure (RVSP) for patients with pulmonary hyper- 
tensionand control group. 
90 
Journal of University of Babylon, Pure and Applied Sciences,Vol.(26), No.(5): 2018  
 
 
FIGURE 5: Tricuspid annular plane systolic excursion (TAPSE)for patients with pul- 
monary hypertension and control group.lin 
 
6 -Discussion 
Pulmonary hypertension is a serious illness that is associated with an increase in 
pul- monary vascular resistance which ensues to cardiac failure, and also lowering 
cardiac output ending in mortality [15]. Multiple ways are found to manage this 
condition, how- ever, the affected patients may be complicated by other illnesses, as 
deficiency in vitamin D during the progress of the disease [16].a link between vitamin D 
and cardiovascular illness was proposed by several other evidences, such as clinical 
trials detecting vitamin D receptors in endothelial cells and vascular smooth muscle cells 
in addition to cardiac cells [17] . 
 
In this study, it was clearly obvious that there is a strong connection between lack of 
vitamin D and pulmonary hypertension in affected patients compared to control group; 
this could suggest that vitamin D is playing a crucial role in maintaining pulmonary arte- 
rial pressure within normal values and its deficiency has a potential promoting effect on 
increasing the prevalence of pulmonary hypertension in affected patients. 
Several studies had consistent outcomes to the findings of this study; Demir et al. 
2013 stated that vitamin D deficiency triggers renin-angiotensin-aldosterone system that 
affects cardiovascular system and the stimulation of this pathway is linked to pulmonary 
hypertension. Moreover, Mirdamadi et al. [18] concluded that replacement therapy of 
vitamin D in patients affected by pulmonary hypertension carries a beneficial outcome on 
improving the dimensions of the right ventricle and that the value of pulmonary artery 
pressure showed some improvement after the course of treatment. 
 
Furthermore, a systematic review and meta-analysis established by Norma et al. [19] 
pointed out that information from several prospective studies predict an inverse relation- 
91 
Journal of University of Babylon, Pure and Applied Sciences,Vol.(26), No.(5): 2018  
 
 
ship between vitamin D and cardiovascular hazard. In contrast to this; another meta- 
analysis done by Mohamed et al. [20]concluded that records offered to date cannot es- 
tablish a statistically significant decrement in mortality and cardiac risk related to vitamin 
D. 
A study by Luke et al. [21] stated that elevated values of RVSP and low values of 
TAPSE are linked to a high and significant mortality risk among patients with pulmonary 
hypertension, and these findings supports those of the current study. A consistent findings 
were pointed out by Stefano et al. [22] in that a base line normal RVSP and TAPSE values 
in pulmonary hypertensive patients were associated with a lower risk of death. 
Other study parameters that showed no statistical significant difference like age and 
gender distributions could be allied to the small number of the study’s participants, or may 
be connected to genetic, environmental, demographic or other unreachable factors. 
 
7 -Conclusions and Recommendations 
This study brings about an outcome that Vitamin D deficiency is more frequent and 
preva- lent among patients with Pulmonary hypertension and right ventricular systolic 
dysfunc- tion compared to control group of subjects, and this may also be linked to 
other car- diovascular risk factors. Additional future studies with a bigger sample size 
are strongly recommended to address other related factors that could not be accomplished 
in this study and to validate benefit of supplementing vitamin D in patients at risk for 
pulmonary hy- pertension who are likely to be vitamin D deficient 
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